Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 4 3Phase 1 2Phase 3 1Phase 1/2 1

Status

Completed 6Active not recruiting 2Unknown 1Terminated 1Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Refractory Differentiated Thyroid Gland Carcinoma 1

Interventions

Carboplatin 98Cisplatin 95pembrolizumab 91Gemcitabine 81Paclitaxel 79Docetaxel 70Capecitabine 64Oxaliplatin 53Fluorouracil 51Specimen Handling 50Magnetic Resonance Spectroscopy 49Bevacizumab 49Radiotherapy 48Dexamethasone 45Cyclophosphamide 45Drug Therapy 39Leucovorin 38Doxorubicin 37Pemetrexed 35Irinotecan 34Injections 30Rituximab 29Vincristine 28Trastuzumab 26Radiosurgery 26Prednisone 26Lenalidomide 25Etoposide 25130-nm albumin-bound paclitaxel 25Radiation 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × dabrafenib × Clear all
NCT06475989 2026-05-15

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Eastern Cooperative Oncology Group

Phase 3 Recruiting
264 enrolled
Head & Neck

Refractory Differentiated Thyroid Gland Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡